Theranostic Expansion Mediso has recently launched Theranostics focused imaging solutions such as SPECT/CT and TheraMAX SPECT/CT, signaling a strategic push into theranostics workflows that combine diagnostic imaging with targeted therapy.

Multimodality Offerings With four imaging modalities (SPECT, PET, CT, MRI) and a track record of multimodality software (InterView FUSION and XP), there is a strong value proposition for customers seeking integrated imaging solutions and unified reporting across nuclear medicine and molecular imaging.

Global Footprint Mediso exports directly and via distributors to over 100 countries, with more than 1,750 imaging systems in operation, highlighting a robust distribution network and international installation base ripe for aftermarket services, upgrades, and cross-region sales.

Strategic Acquisitions Recent activity includes acquiring Bartec technologies and transferring assets from LabLogic, indicating Mediso’s intent to expand capabilities and IP in imaging software and hardware, presenting collaborative sales opportunities with compatible platforms.

R&D and IP Focus Investment in intellectual property, including the Cameleon4 MRI spectrometer IP, shows ongoing innovation and potential for technology licensing, co-development, or upgrade pathways that can be offered to existing customers seeking advanced imaging capabilities.